Transmyocardial CO2 laser revascularization improves symptoms, function, and quality of life: 12-month results from a randomized controlled trial

Combined transmyocardial revascularization and cell-based angiogenic gene therapy increases transplanted cell survival

“…Clinical trials of TMR have reported significant relief of angina (1,7,18), although its mechanism of action in humans is still controversial. TMR may modify the infarct zone to enhance the survival and efficacy of implanted cells by inducing angiogenesis and other effects.…”

Improved quality of life after XeCl excimer transmyocardial laser revascularization: Results of a randomized trial

“…Four out of the five published randomized studies have also assessed QOL. [3,5], detailed QOL results from this last study were later published by Spertus et al [4]), and one did not report the QOL assessment method nor its results (Schofield et al, CO 2 laser [14]). The first three studies reported significant improvements in the TMLR groups compared to the control groups.…”

“…For one of these therapies, transmyocardial laser revascularization (TMLR), significant improvements in QOL have been reported in randomized studies using CO 2 or Ho:YAG lasers [1][2][3][4][5]. For the third clinically used laser, the XeCl excimer laser, uncontrolled studies have also reported promising clinical improvements [6][7][8][9].…”

Cardiac denervation after clinical transmyocardial laser revascularization: short-term and long-term iodine 123–labeled meta-iodobenzylguanide scintigraphic evidence

“…T ransmyocardial laser revascularization (TMLR) is a therapy for severe angina pectoris refractory to antianginal medication, percutaneous transluminal coronary angioplasty, and coronary artery bypass grafting. At low operative risk, CO 2 and Holmium:YAG TMLR relieve angina pectoris [1][2][3][4][5] and improve quality of life (QOL) [1][2][3]6 and exercise time. 1,2,4,5 Furthermore, nonrandomized xenon chloride (XeCl) excimer TMLR achieves similar anginal relief.…”